Viking's Obesity Blockbuster Just Got a Legal Problem

But here's where it gets interesting. Ligand's termination notice doesn't just say "we're done." It demands that Viking grant Ligand a worldwide license to develop or commercialize these therapies itself, in exchange for low single-digit royalty rates going back to Viking. That's a complete reversal: Ligand wants to take the wheel on drugs it originally handed off.

Viking, for its part, is disputing the termination. The company clearly believes it hasn't breached anything.

Why Viking Looked Away

To understand Viking's behavior, you need to understand the gravitational pull of the obesity market. It's like asking why a gold prospector stopped panning in one river when someone found a massive vein in the next one over.

VK2735's numbers are staggering. Two Phase 3 trials (called VANQUISH-1 and VANQUISH-2) are now fully enrolled, with over 5,650 patients combined. An oral version of the drug showed up to 12.2% weight loss in 13 weeks of once-daily dosing. A Phase 3 trial for the oral formulation is expected to launch in Q4 2026.

If VK2735 succeeds, it could compete directly with Eli Lilly's tirzepatide and Novo Nordisk's semaglutide in a market projected to reach hundreds of billions in annual sales. VK0214, a drug for a rare metabolic condition, simply can't compete for attention in that context.

Ligand's Playbook

Ligand isn't some scorned partner acting emotionally. This is a company built on royalties. Its entire business model is licensing assets to other companies and collecting checks when those assets succeed. The company's 2026 revenue guidance sits at $270 to $310 million.

Ligand recently spent $739 million to acquire XOMA Royalty in April 2026, adding over 120 assets to its portfolio. This is a company that thinks in terms of royalty streams the way a landlord thinks in terms of rent payments. When a tenant stops maintaining the property, the landlord wants the keys back.

Ligand is saying: if you won't develop these drugs, give them back so we can find someone who will.

The Legal Question Nobody Can Answer Yet

The core legal question is deceptively simple: what counts as "commercially reasonable efforts"?

VK0214 did show promising Phase 1 results in 2024, with significant reductions in plasma levels of very long-chain fatty acids. But development momentum appears to have stalled since then. Is pausing a program while you pour resources into a potential blockbuster a reasonable business decision, or a breach of your contractual obligations?

Biotech companies make these prioritization calls every day. Resources are finite. But when you've signed a contract promising to develop someone else's intellectual property, "we got busy" might not be a legally sufficient answer.

What Happens Next

Both programs (VK0214 and VK2809) remain listed in Viking's pipeline, though they've been clearly de-emphasized. Ligand says it "intends to vigorously enforce its right to terminate the TRβ program." Viking says it's disputing the termination.

This likely heads to litigation or arbitration, which means months (possibly years) of legal proceedings. For Viking, the best-case scenario is that this becomes a distraction rather than a derailment. The company's obesity program marches forward regardless; the TRβ drugs represent a side story, not the main plot.

For Ligand, the calculus is different. If it can reclaim these programs and find a new partner willing to develop them, it transforms a dormant royalty into an active one. And in a world where metabolic diseases are suddenly the hottest area in pharma, a TRβ agonist with positive clinical data isn't worthless. It just needs someone who actually wants to develop it.

The real lesson here? In biotech partnerships, the contract you signed when you were a tiny preclinical company doesn't go away just because you've outgrown it. Viking bet big on obesity, and that bet is looking smart. But the bill for its earlier commitments just came due.